Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants

Transplantation

Volumn 83, Issue 3, 2007, Pages 290-296

  Weng, Francis L ^a   Patel, Anup M ^a   Wanchoo, Rimda ^a,b   Brahmbhatt, Yasmin ^a   Ribeiro, Kezia ^a   Uknis, Marc E ^a   Mulgaonkar, Shamkant ^a   Mathis, A Scott ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Kidney transplantation; Valganciclovir

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COURSE EVALUATION; COVARIANCE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; ETHNICITY; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; HAZARD ASSESSMENT; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SAMPLE SIZE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; COHORT EFFECT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES;

EID: 33846995945     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000251371.34968.ca     Document Type: Article

References (28)

1. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
2. Cytomegalovirus. Am J Transplant 2004; 4(suppl 10): 51.
3. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
4. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
5. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
6. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811.
7. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
8. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731.
9. Gabardi S, Magee CC, Baroletti SA, et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323.
10. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36: 3107.
11. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
12. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 19: 273.
13. Valganciclovir HCl package insert. Nutley, NJ: Roche Laboratories, Inc., 2006.
14. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
15. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirusresistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615.
16. Akalin E, Bromberg JS, Sehgal V, et al. Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004; 4: 148.
17. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106.
18. Taber DJ, Ashcraft E, Baillie GM, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004; 6: 101.
19. Israni A, Krok K, Cohen D, et al. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients. Transplant Proc 2004; 36: 3019.
20. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
21. Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9: 1697.
22. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 1765.
23. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473.
24. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirusassociated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118.
25. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibodypositive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
26. Yango A, Morrissey P, Zanabli A, et al. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Nephrol Dial Transplant 2003; 18: 809.
27. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006; 81: 1285.
28. Goossens VJ, Blok MJ, Christiaans MH, et al. Early detection of cytomegalovirus in renal transplant recipients: comparison of PCR, NASBA, pp65 antigenemia, and viral culture. Transplant Proc 2000; 32: 155.